Australia markets open in 6 hours 42 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
200.500.00 (0.00%)
As of 1:18PM EDT. Market open.
Full screen
Loading interactive chart…
  • Is CRISPR Therapeutics a Millionaire-Maker Stock?
    Motley Fool

    Is CRISPR Therapeutics a Millionaire-Maker Stock?

    Today, let's turn our attention to gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP). The stock market performance of a clinical-stage biotech like CRISPR Therapeutics is largely tied to the perceived successes (or potential failures) of its pipeline candidates. The company's approach centers on gene editing, which refers to a set of techniques that allow scientists to modify an organism's DNA.

  • CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
    Zacks

    CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

    On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

  • 3 Things About CRISPR Therapeutics That Smart Investors Know
    Motley Fool

    3 Things About CRISPR Therapeutics That Smart Investors Know

    Many biotech companies have been formed hoping to be first to market with CRISPR gene-editing therapies. CRISPR Therapeutics (NASDAQ: CRSP) and its development partner Vertex Pharmaceuticals (NASDAQ: VRTX) are leading the way with the CTX001 therapy for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). On June 11, CRISPR Therapeutics and Vertex held a joint press conference highlighting CTX001 results, which showed that patients in a 22-person phase 1/2 clinical trial are having a "consistent and sustained response to treatment."